Timing light treatment for eastward and westward travel preparation.

Chronobiol Int

Defence Research and Development Canada, Toronto, Canada.

Published: July 2009

Jet lag degrades performance and operational readiness of recently deployed military personnel and other travelers. The objective of the studies reported here was to determine, using a narrow bandwidth light tower (500 nm), the optimum timing of light treatment to hasten adaptive circadian phase advance and delay. Three counterbalanced treatment order, repeated measures studies were conducted to compare melatonin suppression and phase shift across multiple light treatment timings. In Experiment 1, 14 normal healthy volunteers (8 men/6 women) aged 34.9+/-8.2 yrs (mean+/-SD) underwent light treatment at the following times: A) 06:00 to 07:00 h, B) 05:30 to 07:30 h, and C) 09:00 to 10:00 h (active control). In Experiment 2, 13 normal healthy subjects (7 men/6 women) aged 35.6+/-6.9 yrs, underwent light treatment at each of the following times: A) 06:00 to 07:00 h, B) 07:00 to 08:00 h, C) 08:00 to 09:00 h, and a no-light control session (D) from 07:00 to 08:00 h. In Experiment 3, 10 normal healthy subjects (6 men/4 women) aged 37.0+/-7.7 yrs underwent light treatment at the following times: A) 02:00 to 03:00 h, B) 02:30 to 03:30 h, and C) 03:00 to 04:00 h, with a no-light control (D) from 02:30 to 03:30 h. Dim light melatonin onset (DLMO) was established by two methods: when salivary melatonin levels exceeded a 1.0 pg/ml threshold, and when salivary melatonin levels exceeded three times the 0.9 pg/ml sensitivity of the radioimmunoasssy. Using the 1.0 pg/ml DLMO, significant phase advances were found in Experiment 1 for conditions A (p < .028) and B (p < 0.004). Experiment 2 showed significant phase advances in conditions A (p < 0.018) and B (p < 0.003) but not C (p < 0.23), relative to condition D. In Experiment 3, only condition B (p < 0.035) provided a significant phase delay relative to condition D. Similar but generally smaller phase shifts were found with the 2.7 pg/ml DLMO method. This threshold was used to analyze phase shifts against circadian time of the start of light treatment for all three experiments. The best fit curve applied to these data (R(2) = 0.94) provided a partial phase-response curve with maximum advance at approximately 9-11 h and maximum delay at approximately 5-6 h following DLMO. These data suggest largest phase advances will result when light treatment is started between 06:00 and 08:00 h, and greatest phase delays will result from light treatment started between 02:00 to 03:00 h in entrained subjects with a regular sleep wake cycle (23:00 to 07:00 h).

Download full-text PDF

Source
http://dx.doi.org/10.1080/07420520903044331DOI Listing

Publication Analysis

Top Keywords

light treatment
36
experiment normal
12
normal healthy
12
women aged
12
underwent light
12
treatment times
12
phase advances
12
treatment
10
light
10
phase
9

Similar Publications

Curcumin-coated iron oxide nanoparticles for photodynamic therapy of breast cancer.

Photochem Photobiol Sci

January 2025

Nanosensors Laboratory, Research & Development Institute, University of Vale do Paraíba, Av. Shishima Hifumi, 2911, Urbanova, São José dos Campos, São Paulo, Brazil.

Breast cancer is the deadliest cancer among women and its treatment using traditional methods leads the patient to experience adverse effects. However, photodynamic therapy (PDT) is a non-invasive therapy modality that works through a photosensitizing agent, which treating activated by a suitable light source, releases reactive oxygen species capable of treating cancer. Furthermore, recent research indicates that combining PDT and nanoparticles can enhance therapeutic effects.

View Article and Find Full Text PDF

Bone Marrow Aspiration Concentrate in the Treatment of Osteoarthritis: A Review of its Current Clinical Application.

Tissue Eng Regen Med

January 2025

Department of Orthopaedics, Dongguk University Ilsan Hospital, Dongguk-Ro 27, Goyang, Republic of Korea.

Background: Bone marrow aspiration concentrate (BMAC) has gained acceptance as a safe orthobiologic for treating osteoarthritis (OA), despite lacking robust supporting evidence. Although several publications have documented the use of BMAC in OA, evidence confirming its unequivocal efficacy remains limited.

Methods: This review aims to summarize the current clinical evidence regarding BMAC as a therapeutic for OA, while also presenting the author's perspective.

View Article and Find Full Text PDF

Background: Mood influences smoking behavior, with sex and sex hormones potentially complicating these relationships. We explored associations between Profile of Mood States (POMS) and Questionnaire on Smoking Urges (QSU) - Brief with sex hormones in men and women who smoke.

Methods: This is a secondary analysis of treatment non-responders from a smoking cessation randomized trial investigating exogenous progesterone's efficacy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!